Soumya D Chakravarty Selected Research

golimumab

12/2022	Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study.
8/2022	Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry.
1/2022	Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
1/2022	Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
12/2021	Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
9/2021	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
11/2020	Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
11/2020	Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.
1/2020	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
1/2020	Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Soumya D Chakravarty Research Topics

Disease

38	Psoriatic Arthritis 02/2024 - 01/2019
19	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2024 - 01/2018
9	Arthritis (Polyarthritis) 02/2024 - 01/2020
7	Pain (Aches) 02/2024 - 01/2020
7	Infections 10/2023 - 01/2019
6	Ankylosing Spondylitis 12/2023 - 11/2020
6	Rheumatoid Arthritis 08/2022 - 07/2013
4	Sacroiliitis 12/2023 - 10/2021
4	Tuberculosis (Tuberculoses) 10/2023 - 02/2007
3	Opportunistic Infections (Opportunistic Infection) 10/2023 - 01/2021
3	Crohn Disease (Crohn's Disease) 10/2023 - 01/2019
3	Skin Diseases (Skin Disease) 01/2023 - 09/2022
3	Fatigue 12/2022 - 01/2020
3	Inflammation (Inflammations) 09/2022 - 03/2008
3	Necrosis 01/2021 - 01/2019
2	Neoplasms (Cancer) 10/2023 - 01/2022
2	Joint Diseases (Joint Disease) 10/2023 - 01/2023
2	Axial Spondyloarthritis 08/2023 - 01/2023
2	Spondylitis 08/2023 - 01/2020
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 10/2019
2	Granuloma 10/2012 - 03/2008
1	Ulcerative Colitis 10/2023
1	Back Pain (Backache) 01/2023
1	Ankylosis 12/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Rheumatic Diseases (Rheumatism) 11/2020
1	Multiple Sclerosis 10/2012
1	Sarcoidosis (Schaumann Disease) 10/2012
1	Chronic Urticaria 12/2011
1	Latent Tuberculosis 03/2008

Drug/Important Bio-Agent (IBA)

24	guselkumabIBA 02/2024 - 01/2021
10	golimumab FDA Link 12/2022 - 01/2020
8	Tumor Necrosis Factor InhibitorsIBA 01/2024 - 01/2019
8	Ustekinumab (CNTO 1275)FDA Link 01/2023 - 01/2019
6	Interleukin-23 (Interleukin 23)IBA 01/2024 - 01/2022
6	Monoclonal AntibodiesIBA 12/2022 - 11/2020
5	InterleukinsIBA 01/2024 - 01/2021
5	Immunoglobulin A (IgA)IBA 01/2024 - 01/2022
5	Interleukin-17 (Interleukin 17)IBA 01/2023 - 10/2019
4	ametantrone (HAQ)IBA 02/2024 - 09/2022
4	Antirheumatic Agents (DMARD)IBA 02/2024 - 01/2021
4	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2023
4	Methotrexate (Mexate)FDA LinkGeneric 10/2023 - 01/2019
3	Prostaglandins AIBA 12/2023 - 01/2019
3	Adalimumab (Humira)FDA Link 11/2023 - 01/2019
3	Interleukin-12 (IL 12)IBA 01/2023 - 01/2020
3	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2023 - 01/2020
3	Interleukin-23 Subunit p19IBA 12/2022 - 01/2021
3	Infliximab (Remicade)FDA Link 08/2022 - 01/2019
2	omega-Chloroacetophenone (Mace)IBA 10/2023 - 01/2022
2	CytokinesIBA 01/2023 - 01/2023
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2019
2	C-Reactive ProteinIBA 10/2021 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2020 - 03/2008
2	Etanercept (Enbrel)FDA Link 01/2020 - 01/2019
1	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2023
1	risankizumabIBA 01/2023
1	Interleukin-10 (Interleukin 10)IBA 01/2023
1	HLA-B38 AntigenIBA 01/2023
1	HLA-B13 AntigenIBA 01/2023
1	HLA-B57 antigenIBA 01/2023
1	Antigen-Antibody Complex (Immune Complex)IBA 12/2022
1	AS 8IBA 09/2021
1	Certolizumab Pegol FDA Link 01/2020
1	AntigensIBA 01/2020
1	Phosphodiesterase 4 InhibitorsIBA 10/2019
1	Immunologic Factors (Immunomodulators)IBA 01/2019
1	SteroidsIBA 01/2018
1	Phosphotransferases (Kinase)IBA 07/2013
1	Interferon-betaIBA 10/2012
1	Interferon Type IIBA 10/2012
1	Rituximab (Mabthera)FDA Link 12/2011
1	IgE Receptors (Fc epsilon RI)IBA 12/2011
1	AutoantibodiesIBA 12/2011
1	Chemokine ReceptorsIBA 02/2007

Therapy/Procedure

8	Therapeutics 08/2023 - 03/2008
3	Biological Therapy 12/2022 - 01/2019
1	Subcutaneous Injections 10/2023
1	Time-to-Treatment 01/2023
1	Activities of Daily Living (ADL) 03/2021
1	Injections 01/2020